Pain control in patients with cancer

ONCOLOGY

Volumn 13, Issue 5 SUPPL., 1999, Pages 9-14

  Levy, Michael H ^a,b  

^a FOX CHASE CANCER CENTER   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OPIATE AGONIST;

ADVANCED CANCER; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER PATIENT; HUMAN; REVIEW; TREATMENT INDICATION;

ANALGESICS, OPIOID; DRUG ADMINISTRATION ROUTES; HUMANS; NEOPLASMS; PAIN; PHYSICIAN'S ROLE;

EID: 0033049154     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Cleeland CS, Gonin R, Hatfield AK, et al: Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 330:592-596, 1994.
2. Coyle N, Adelhardt J, Foley KM, et al: Character of terminal illness in the advanced cancer patient: Pain and other symptoms during last four weeks of life. J Pain Symptom Manage 5:83-93, 1990.
3. Portenoy RK, Miransky J, Thaler HT, et al: Pain in ambulatory patients with lung or colon cancer: Prevalence, characteristics, and effect. Cancer 70:1516-1624, 1992.
4. Ventafridda V, Ripamonti C, DeConno F, et al: Symptom prevalence and control during cancer patients' last days of life. J Palliat Care 6:7-11, 1990.
5. Grond S, Zech D, Diefenbach C, et al: Prevalence and pattern of symptoms in patients with cancer pain: A prospective evaluation of 1635 cancer patients referred to a pain clinic. J Pain Symptom Manage 9:372-382, 1994.
6. Foley KM: Competent care for the dying instead of physician-assisted suicide. New Engl J Med 336: 54-58, 1997.
7. Jacox AK, Carr DB, Payne R, et al: Management of cancer pain. Clinical practice guideline no. 9. Rockville, Md.: Agency for Health Care Policy and Research, 1994. (AHCPR publication no. 94-0592).
8. Doyle D, Hanks GWC, MacDonald N, (eds): Oxford Textbook of Palliative Medicine. Oxford, Oxford Medical Publishing, 1997.
9. Twycross R: Pain Relief in Advanced Cancer. London, Churchill Livingstone, 1994.
10. Levy MH: Pharmacolgoic treatment of cancer pain. New Engl J Med 335:1124-1132, 1996.
11. th ed): Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain. Skokie, American Pain Society, 1999.
12. Arbit E, (eds): Management of Cancer-Related Pain. Mount Kisco, Futura Publishing Co Inc, 1993.
13. Patt RB, (ed): Cancer Pain. Philadelphia. J. B. Lippincott Co, 1993.
14. Rosen SM: Procedural control of cancer pain. Semin Oncol 21:740-747, 1994.
15. Bottomley DM, Hanks GW: Subcutaneous midazolam infusion in palliative care. J Pain Symptom Manage 5:259-261, 1990.
16. Greene WR, Davis WH: Titrated intravenous barbituates in control of symptoms in patients with terminal cancer. Southern Med J 84:332-337, 1991.
17. Ferrer-Brechner T: The management of pain associated with malignancy. Semin Anesthes 4:313-322, 1985.
18. Levy MH: Integration of pain management into comprehensive cancer care. Cancer 63:2328-2335, 1989.
19. Cherny NJ, Portenoy RK: The management of cancer pain. Cancer J Clin 44:262-303, 1994.
20. Serlin RC, Mendoza TR, Nakamura Y, et al: When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 61:277-284, 1995.
21. Galer BS, Coyle N, Pasternak GW, et al: Individual variability in the response to different opioids: Report of five cases. Pain 49:87-91, 1992.
22. Crews JC, Sweeney NJ, Denson DD: Clinical efficacy of methadone in patients refractory to other mu-opioid receptor agonist analgesics for management of terminal cancer pain: Case presentations and discussion of incomplete cross-tolerance among opioid agonist analgesics. Cancer 72:2266-2272, 1993.
23. MacDonald N, Der L, Allan S, et al: Opioid hyperexcitability: The application of alternate opioid therapy. Pain 53:353-355, 1993.
24. de Stoutz ND, Bruera E, Suarez-Almazor M: Opioid rotation for toxicity reduction in terminal patients. J Pain Symptom Manage 10:378-384, 1995.
25. Thirlwell MP, Sloan PA, Maroun JA, et al: Pharmacokinetics and clinical efficacy of oral morphine solution and controlled-release morphine tablets in cancer patients. Cancer 63:2275-2283, 1989.
26. Ferrell B, Wisdom C, Wenzl C, et al: Effects of controlled-release morphine on quality of life for cancer pain. Oncol Nurs Forum 16:521-526, 1989.
27. Bruera E, Belzile M, Pituskin E, et al: Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain. J Clin Oncol 16:3222-3229, 1998.
28. Kaplan R, Parris WCV, Citron ML, et al: Comparison of controlled-release and immediate-release oxycodone tablets in patients with cancer pain. J Clin Oncol 16: 3230-3237, 1998.
29. Payne R: Transdermal fentanyl: Suggested recommendations for clinical use. J Pain Symptom Manage 7(suppl):S40-44, 1992.
30. Ahmedzai S, Brooks D: Transdermal fentanyl versus sustained-release oral morphine in cancer pain: Preference, efficacy, and quality of life. J Pain Symptom Manage 13:254-261, 1997.
31. Hays H, Hagen N, Thirlwell M, et al: Comparative clinical efficacy and safety of immediate release and controlled release hydromorphone for chronic severe cancer pain. Cancer 74:1808-1816, 1994.
32. Portenoy RK, Hagen NA: Breakthrough pain: Definition, prevalence and characteristics. Pain 41:273-281, 1990.
33. Christie JM, Simmonds M, Patt R, et al: Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain. J Clin Oncol 16:3238-3245, 1998.
34. Portenoy RK, Payne R, Coluzzi P, et al: Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: A controlled dose titration study. Pain 79:303-312, 1999.
35. Levy MH: Constipation and diarrhea in cancer patients. Cancer Bull 43:412-422, 1991.
36. Bruera E, Macmillan K, Hanson J, et al: The cognitive effects of the administration of narcotic analgesics in patients with cancer pain. Pain 39:13-16, 1989.
37. Vainio A, Ollila JH, Matikainen E, et al: Driving ability in cancer patients receiving long-term morphine analgesia. Lancet 346:667-670, 1995.
38. Ripamonti C, Groff L, Brunelli C, et al: Switching from morphine to oral methadone in treating cancer pain: What is the equianalgesic dose ration? J Clin Oncol 16:3216-3221, 1998.
39. Eisenberg E, Berkey CS, Carr DB, et al: Efficacy and safety of nonsteroidal antiinflammatory drugs for cancer pain: A meta-analysis. J Clin Oncol 12:2756-2765, 1994.
40. Body JJ, Bartl R, Burckhardt P, et al: Current use of bisphosphonates in oncology. J Clin Oncol 16:3890-3899, 1998.
41. Watanabe S, Bruera E: Corticosteroids as adjuvant analgesics. J Pain Symptom Manage 9:442-445, 1994.
42. Watson CPN: Antidepressant drugs as adjuvant analgesics. J Pain Symptom Manage 9:392-405, 1994.
43. McQuay H, Carrol D, Jadad AR, et al: Anticonvulsant drugs for management of pain: A systematic review. Brit Med J 311:1047-1052, 1995.
44. Backonja M, Beydoun A, Edwards KR, et al: Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus. J Amer Med Assoc 280:1831-1836, 1998.
45. Rowbotham M, Harden N, Stacey B, et al: Gabapentin for the treatment of postherpetic neuralgia. J Amer Med Assoc 280:1837-1842, 1998.
46. Portenoy RK: Chronic opioid therapy in nonmalignant pain. J Pain Symptom Manage 5(suppl):S46-62, 1990.
47. Brookoff D, Polomano R: Treating sickle cell pain like cancer pain. Ann Intern Med 116:364-368, 1992.
48. Zenz M, Strumpf M, Tryba M: Long-term oral opioid therapy in patients with chronic non-malignant pain. J Pain Symptom Manage 7:69-77, 1992.